S
Stoke Therapeutics
Biotech & Life Sciences · Bedford, United States · Founded 2014 · IPO 2019
Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment of severe genetic diseases MoreLess
Stoke Therapeutics is at the forefront of developing innovative treatments for severe genetic diseases. The company focuses on conditions caused by the loss of function in a single gene, aiming to restore missing proteins through precise upregulation of protein expression. Stoke Therapeutics operates primarily in the biotechnology and pharmaceutical markets, targeting patients with rare genetic disorders. Their business model revolves around the research and development of disease-modifying therapies, leveraging their proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform. This platform allows them to deliver highly precise, durable, and controllable treatments to a broad range of tissues. Stoke Therapeutics generates revenue through partnerships, licensing agreements, and eventually, the commercialization of their therapies. The company serves a niche market of patients with unmet medical needs, providing hope for those affected by debilitating genetic conditions.
Keywords: genetic diseases, protein expression, TANGO platform, biotechnology, pharmaceutical, rare disorders, gene therapy, disease-modifying, precision medicine, upregulation.
Company overview
Stoke Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2014
- Headquarters
- Bedford, United States
- Employees
- 219
- Open positions
- 16
- Dealroom signal
- 91.6
Valuation & funding
Stoke Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Mar 2024 | $125M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Nov 2020 | $105M | — | Undisclosed | ↗ |
| IPOOther financing | Jun 2019 | $142M | $566M | Undisclosed | — |
| SERIES BOther financing | Oct 2018 | $90M | $360M | Alexandria Venture Investments · Cormorant Asset Management · RA Capital Management · Perceptive Advisors | ↗ |
| SERIES AOther financing | Jan 2018 | $40M | $160M | Apple Tree Partners | — |
| SPINOUTOther financing | Jan 2014 | Cold Spring Harbor Laboratory | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $184M | 0% | −$19M | -10.2% |
| 2025 | $184M | +404.5% | −$19M | -10.2% |
| 2024 | $37M | +316.3% | −$99M | -271.4% |
| 2023 | $8.8M | -29.2% | −$112M | -1279.1% |
| 2022 | $12M | — | −$104M | -841.2% |
| 2021 | $0 | — | −$86M | — |
| 2020 | $0 | — | −$53M | — |
Growth signals
Stoke Therapeutics website traffic
Latest recorded traffic for Stoke Therapeutics is 13K monthly website visits, down 18.8% over the last three months. Stoke Therapeutics's team grew 41.3% over the past year.
Hiring
Open positions at Stoke Therapeutics
Current openings linked to this company in Dealroom.
Comparisons
Stoke Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Stoke Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Stoke Therapeutics has talent and traffic
team presence
In the news
Latest news about Stoke Therapeutics
Recent press, funding announcements, and product moves mentioning Stoke Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Stoke Therapeutics
An AI-synthesized read of the highest-engagement posts about Stoke Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Stoke Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.